赖色甘酯(Cromoglycate lisetil hydrochloride)

概要

基本信息

药物类型

小分子化药

别名

5-[3-(2-carboxy-4-oxo-4H-5-chromenyloxy)-2-hydroxypropoxy]-4-oxo-4H-2-chromenecarboxylic acid、Cromoglicate、Cromoglicate lisetil

+ [8]

靶点-

作用方式

抑制剂、稳定剂

作用机制

组胺释放抑制剂、肥大细胞稳定剂

治疗领域

肿瘤免疫系统疾病感染+ [5]

在研适应症-

非在研适应症

哮喘特应性皮炎髓性系统性肥大细胞增多症+ [6]

原研机构

Kyoto Pharmaceutical Industries Ltd.

在研机构-

非在研机构

LEO Pharma A/S

Asahi Kasei Corp.

Leo Pharma, Inc.

+ [1]

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C33H38Cl2N2O12

InChIKeyVZZTWOVKCVPTSM-FJSYBICCSA-N

CAS号110816-78-9

查看全部结构式(3)

关联

13

项与赖色甘酯相关的临床试验

CTIS2023-507541-29-00

/ Recruiting临床2期IIT

EFFICACY AND SAFETY OF CROMOGLYCATE AS A NEW SYMPTOMATIC TREATMENT IN PATIENTS WITH MULTIPLE SCLEROSIS - CAMINA

开始日期2024-10-21

申办/合作机构-

NCT03202147

/ Withdrawn临床2期

A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)

This is a Phase II, randomized, double-blinded, placebo-controlled study for subjects with evidence of PSCI.

开始日期2023-12-01

申办/合作机构

AZTherapies, Inc.

NCT04408664

/ Terminated临床3期IIT

WP3-Influence of Cromones on EVH-test in Young (Elite) Athletes Who Tested Positive for EIB (=Exercise Induced Bronchoconstriction)

This is a randomized, double-blinded, placebo-controlled trial of nebulized Sodium Cromoglycate (SCG) (Lomudal®) versus NaCl0.9% in athletes (11-18 year) with exercise-induced bronchoconstriction (EIB).

开始日期2021-04-06

申办/合作机构

Katholieke Universiteit Leuven

[+2]

100 项与赖色甘酯相关的临床结果

登录后查看更多信息

100 项与赖色甘酯相关的转化医学

登录后查看更多信息

100 项与赖色甘酯相关的专利（医药）

登录后查看更多信息

1,025

项与赖色甘酯相关的文献（医药）

2025-03-04·Nanomedicine

Formation and evaluation of doxorubicin and cromoglycate metal–organic framework for anti-cancer activity

Article

作者: Hamadneh, Imad ; Shalan, Naeem ; Alshaer, Walhan ; Abu Saleem, Ebaa ; Lafi, Zainab

AIMSWe develop and evaluate copper-based metal-organic frameworks (Cu-MOFs) incorporating cromolyn as a linker to enhance structural stability, drug delivery efficiency, and therapeutic potential, particularly for breast cancer treatment.MATERIALS & METHODSTwo Cu-MOF formulations were synthesized: Cu-MOFs-BDC-DOX (using terephthalic acid) and Cu-MOFs-CROMO-DOX (using cromolyn as a linker). Characterization was performed using SEM/TEM for morphology, and FTIR, XRD, and TGA to confirm structural integrity. Drug encapsulation efficiency and release profiles were assessed, followed by in vitro cytotoxicity, cell migration, and colony formation assays using MDA-MB-231 breast cancer cells.RESULTSBoth formulations demonstrated a high encapsulation efficiency (83-91%) and sustained drug release over 48 h at pH 7.4. Cu-MOFs-CROMO-DOX exhibited superior cytotoxicity with an IC50 of 0.88 ± 0.07 µM compared to 7.1 ± 0.11 µM for Cu-MOFs-BDC-DOX. Both formulations inhibit cancer cell migration and colony formation in a dose-dependent manner.CONCLUSIONSThe Cu-MOFs-CROMO-DOX formulation demonstrated enhanced therapeutic potential, outperforming its counterpart in targeting breast cancer cells. This study highlights the promise of MOF-based nanocarriers in overcoming the limitations of conventional chemotherapy, offering a pathway to more effective and targeted cancer treatments with reduced side effects.

2025-01-01·Journal of Allergy and Clinical Immunology

Omalizumab for mast cell disorders

作者: Akin, Cem

A review.The goals of treatment in MCD include avoidance of known triggers; treatment of the underlying pathol. when known; and pharmacotherapy targeting mast cell mediators such as with H1 and H2 histamine receptor blockers, leukotriene pathway modifiers, and mast cell stabilizers (which traditionally include cromolyn and ketotifen but may also be expanded to include calcineurin inhibitors and currently investigational agents such as Bruton tyrosine kinase [BTK] inhibitors).Well-designed prospective trials are needed to gain more information on the effect of omalizumab on mastocytosis and idiopathic anaphylaxis and determine the best approach to preventive therapy of anaphylaxis in these patient populations.Those subsets of patients with severe anaphylaxis or MCAS (with or without known mastocytosis) and an IgE-dependent trigger identified at diagnosis or during follow-up who experience breakthrough severe MCA events despite their best efforts at trigger avoidance and preventive antimediator therapy appear particularly well suited to benefit from omalizumab therapy.

2024-11-01·iScience

Tumor-infiltrating mast cells confer resistance to immunotherapy in pancreatic cancer

Article

作者: Logsdon, Craig D. ; Wang, Huamin ; Ji, Baoan ; Qiu, Suimin ; Huang, Lu ; Ma, Ying ; Hwu, Patrick ; Feng, Jingyan ; Logsdon, Craig D ; Zhao, Xiangqin

Pancreatic ductal adenocarcinoma (PDAC) exhibits an immunosuppressive tumor microenvironment (TME) contributing to its therapeutic resistance. Following our previous studies, we report that mast cells infiltrating the PDAC TME foster this immunosuppression and desmoplasia. Mast cell infiltration correlated with human PDAC progression, and genetic or pharmacological mast cell depletion reduced tumor growth and desmoplasia while enhancing survival in mouse PDAC models. Mechanistically, mast cell-derived IL-10 promoted PDAC progression. Strikingly, combining an agonistic anti-OX40 immunotherapy with mast cell blockade synergistically elicited durable anti-tumor immunity, marked by increased infiltration of CD8⁺ T effector cells expressing granzyme B and dramatic survival benefit unachievable with either approach alone. An OX40-associated gene signature correlated with improved survival in human PDAC, supporting therapeutic translation. Our findings establish mast cells as promoters of the suppressive PDAC TME and rational targets for combination immunotherapy. Targeting this mast cell-mediated resistance mechanism could overcome immunotherapy failure in PDAC.

100 项与赖色甘酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB01003

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
斑块状银屑病	临床2期	德国	Leo Pharma, Inc.	2012-11-01
髓性系统性肥大细胞增多症	临床2期	德国	Leo Pharma, Inc.	2012-10-01
色素性荨麻疹	临床2期	德国	Leo Pharma, Inc.	2012-10-01
哮喘	临床2期	日本	-	-
特应性皮炎	临床2期	日本	-	-
肥大细胞增多症	临床2期	德国	LEO Pharma A/S	-
银屑病	临床2期	-	Asahi Kasei Corp.	-
银屑病	临床2期	-	Kyoto Pharmaceutical Industries Ltd.	-
银屑病	临床2期	德国	LEO Pharma A/S	-
过敏性鼻炎	临床2期	日本	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACAAI2022	N/A	侵袭性系统性肥大细胞增多症 KITD816V mutation	-	Midostaurin 30mg/m^2 every 12 hours	憲艱遞齋襯願鬱衊願醖(範餘糧廠範壓構糧製淵) = 淵膚壓膚積簾艱遞構構壓範鹹範憲廠醖艱淵構 (夢繭淵簾顧簾鏇鏇醖遞, 2.9 ~ 5.5) 更多	积极	2022-11-10
				H1 and H2 antihistamines + oral cromolyn	遞衊鹽鏇遞鑰選餘淵憲(餘淵積齋壓願餘窪積憲) = 網鑰願鑰鹽膚鹽範製糧蓋壓淵簾範觸窪壓淵願 (窪淵糧醖範願膚鑰繭網 )